Business Model

Our Unique Business Model

At PeptiDream, we are aiming to discover innovative therapeutics through various business models leveraging our proprietary drug discovery platform, PDPS (Peptide Discovery Platform System)

Our business has four key features:

①World-leading, proprietary peptide drug discovery technology platform
②Global network to lead and expand the field of peptide drug discovery
③Robust drug discovery and development pipeline
④High growth potential enabled by unique business model

Leveraging our strengths and distinctive capabilities, we are striving to build and maintain our position as a “Drug Discovery Powerhouse” at the center of the global ecosystem of peptide drug discovery.

① World-Leading, Proprietary Peptide Drug Discovery Technology Platform

PDPS is a versatile drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds. The platform enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns.

In addition to the 20 canonical amino acids, PDPS can incorporate over 3,000 non-canonical amino acids into macrocyclic peptides, which allows for flexible design of libraries comprising of trillions of structurally diverse peptides for various purposes.

By leveraging our expertise and experience gained through working on numerous drug discovery programs over the years, PDPS is constantly evolving. For example, we developed an automated PDPS platform by combining our experience working with PDPS and industry-leading robotic technology. This automated platform improves the efficiency of hit screening and enables more sophisticated screening campaigns which were difficult to conduct with conventional manual operations.

PDPS is protected by a robust patent portfolio. We have an exclusive license from the University of Tokyo for the related patents, and are constantly building our own patent estate as PDPS continues to evolve.

Many disciplines are required in R&D to turn hit peptides obtained by PDPS into a candidate compound for clinical development. Our world-class teams in medicinal chemistry, biology, structural biology, bioinformatics, modeling, pharmacology, ADME, and translational research capabilities can perform all activities required in the drug discovery process from hit identification, optimization, preclinical research, IND preparation studies and early-stage clinical trials.

Read more about PDPS here.

② Global Network to Lead and Expand the Field of Peptide Drug Discovery

With PDPS as our core technology, we are expanding our partnerships with various pharmaceutical and biotech companies around the world, and aim to become the center of the global ecosystem of peptide drug discovery.

The pharmaceutical R&D process generally follows the chart below. Our focus is on the drug discovery research stage, where we can fully leverage our strengths. From clinical trials and onwards, we engage in alliances with partners with expertise in pharmaceutical development and commercialization who can eventually bring our products into the market.

We are also creating a drug discovery network based on a common platform by licensing PDPS in the form of technology transfers to pharmaceutical companies globally. While we are turning PDPS into an industry-standard platform technology, we are also building our expertise and know-how to lead and maintain a sustainable partnership with our collaborators.

Our strategic alliances are not only with major pharmaceutical companies, but also with biotechs and research institutions with innovative technologies. By integrating various complementary technologies, we are expanding our scope to other drug modalities beyond peptides, such as oligonucleotides and radiopharmaceuticals, to discover and develop innovative drugs which have been challenging to materialize with past methods.

We are also actively building an internal pipeline of internal discovery programs, and our network of partners also plays an important role in out-licensing activities for these programs from our pipeline.

We are striving to strengthen our position as a "Drug Discovery Powerhouse" that can continuously generate new technologies and drug candidates, and establish a leadership role in the global drug discovery landscape is important to drive peptide drug discovery.

③ Robust drug discovery and development pipeline

Through collaborations with pharmaceutical companies, strategic alliances and in-house programs, we currently have large number of projects in a wide range of therapeutic areas including oncology, CNS, and immunology.

By having a large number of projects in our pipeline, we diversify the risk, which is inherently high in the drug discovery industry, in our business model.

In addition to peptide therapeutics, we are actively finding new applications for our macrocyclic peptides. From the hit peptides that we obtain through PDPS, we currently are pursuing 3 modalities: ① peptides / small molecules, ② peptide drug conjugates (PDC), and ③ multifunctional peptide conjugates (MPC) drugs).

For further information about our drug discovery approach, see here.

PDRadiopharma Inc., our wholly owned subsidiary, has a fully integrated radiopharmaceutical business and has functions including R&D, manufacturing, and sales. PDRadiopharma currently commercializes 24 diagnostic and 8 therapeutic products (3 product categories) in Japan, and is growing its development pipeline of next-generation radiopharmaceuticals. PDRadiopharma is also working towards maximizing the value of its products by actively engaging in adding indications and software development.

For more information about PDR Pharma’s pipeline, see:
https://www.pdradiopharma.com/en/about/developmentinfo/newdrugdevelopment/

④ High Growth Potential Enabled by Unique Business Model

With 4 highly complementary and synergistic business strategies, we are implementing a unique business model to achieve high growth potential while maintaining stable profitability.

Through a milestone-based revenue model, our Drug Discovery and Development Business Segment has been profitable with stable growth, even though pharmaceutical R&D typically involves long-term return on investment. We are also building a robust pipeline with high earning potential for future growth.

We have been steadily expanding our business and pipeline through positive operating cash flow annually, and have not raised capital through equity since we went public in 2013.

Our PDRadiopharma subsidiary conducts R&D, manufacture and commercialize radiopharmaceutical products. By combining PeptiDream’s and PDRadiopharma’s technologies, expertise, and alliance networks, we are expanding our radiopharmaceutical business by discovering and developing novel radiopharmaceutical agents, including RI-PDC (peptide-radionuclide conjugates), and in-licensing promising radiopharmaceuticals for the Japanese market from overseas.

For more information about PDRadiopharmapharma:
https://www.pdradiopharma.com/en/

PD／ＰＤＲadiopharmaceutical Product Offerings: